SynCardia Total Artificial Heart supports patient through complex re-transplant journeyTUCSON, Ariz., April 15, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today highlighted the successful use of the SynCardia Total Artificial Heart (“STAH”) as a bridge to heart transplantation at Texas Children’s Hospital (“Texas Children’s”), supporting a 21-year-old patient through a complex re-transplant journey. Texas Children’s recently featured the case of Gregory, a now 21-year-old patient who had received his first heart transplant at Texas Children’s in 2017 at the age of 13 following multiple congenital heart defects. In early 2025, Gregory was admitted to Texas Children’s after presenting with chest pain and was diagnosed with rejection of his first transplanted heart. With his original transplant no longer viable and a donor heart unavailable, surgeons implanted the STAH to provide full circulatory support. Gregory was supported on the STAH for approximately two and a half months before a suitable donor heart became available. He subsequently underwent successful heart transplantation and, following an extended recovery, was discharged from the hospital. The STAH is designed to replace the function of both ventricles in patients with end-stage biventricular failure, enabling stabilization, organ recovery, and improved candidacy for transplantation. Its use in complex clinical scenarios, including re-transplantation in young adults with congenital heart disease, demonstrates the flexibility and durability of the therapy in supporting some of the most critically ill patients. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, commented, “Performing a successful re-transplantation in a young adult with congenital heart disease is among the most complex scenarios in cardiac surgery. In this instance at Texas Children’s, the STAH allowed the clinical team to stabilize the patient and effectively buy time following the diagnosis of rejection until a suitable donor organ became available. Although the support period in this case was relatively short compared with many other cases, the immediate availability of the STAH was essential in enabling a successful outcome. Experiences like this also reinforce why we are developing the Emperor Total Artificial Heart, our next generation fully implantable total artificial heart, designed to remove the external driver and ultimately serve as a potential alternative to heart transplantation for certain patients.” Picard Medical continues to support leading transplant centers across the United States and globally, advancing the use of the STAH to improve outcomes for patients with advanced heart failure. Picard is also advancing development of the Emperor Total Artificial Heart, a fully implantable next-generation device designed to expand access to long-term mechanical circulatory support without the need for external pneumatic drivers. About Texas Children’s Hospital Texas Children’s, a nonprofit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children’s hospital in Texas and among the top in the nation, Texas Children’s has garnered widespread recognition for its expertise and breakthroughs in pediatric and women’s health. The system includes the Texas Children’s Duncan NRI; the Feigin Tower for pediatric research; Texas Children’s Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children’s Hospital West Campus, a community hospital in suburban West Houston; Texas Children’s Hospital The Woodlands, the first hospital devoted to children’s care for communities north of Houston; and Texas Children’s Hospital North Austin, the new state-of-the-art facility providing world-class pediatric and maternal care to Austin families. The organization also created Texas Children’s Health Plan, the nation’s first HMO focused on children; Texas Children’s Pediatrics, the largest pediatric primary care network in the country; Texas Children’s Urgent Care clinics that specialize in after-hours care tailored specifically for children; and a global health program that is channeling care to children and women all over the world. Texas Children’s Hospital is affiliated with Baylor College of Medicine. For more information, visit www.texaschildrens.org. About Picard Medical and SynCardia Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Additional information about the Company, including risk factors that may affect the Company’s business, financial condition, and results of operations, is contained in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge on the SEC’s website at http://www.sec.gov and on the Company’s investor relations website at https://picardmedical.com/. Contact: Investors Eric Ribner Managing Director LifeSci Advisors LLC eric@lifesciadvisors.com Picard Medical, Inc./SynCardia Systems, LLC IR@picardmedical.com General/Media Brittany Lanza blanza@syncardia.com

Segment showcases SynCardia Total Artificial Heart supporting patients with advanced heart failure and next-generation development programs Segment showcases SynCardia Total Artificial Heart supporting patients with advanced heart failure and next-generation development programs

New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system

– Successful heart transplant case following an implanted SynCardia total artificial heart reported at hospital with one of the largest heart transplant programs in the country -TUCSON, Ariz., Feb. 12, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that University of California, San Francisco (UCSF) Health has successfully performed its first heart transplant in a patient who had previously been supported with the SynCardia Total Artificial Heart, marking an important clinical milestone in the treatment of advanced biventricular heart failure. UCSF Health is the U.S. News & World Report 2025-2026 top-ranked hospital in California. UCSF announced in a press release yesterday that a 37-year-old patient from California’s Central Valley was admitted to UCSF in August 2025 with end-stage heart failure. Within weeks, surgeons implanted the SynCardia Total Artificial Heart (STAH) manufactured by Picard Medical Inc., through its wholly owned subsidiary SynCardia Systems LLC. It was the fifth patient that UCSF Health had implanted with a SynCardia Total Artificial Heart. The six-hour procedure took place at the Helen Diller Medical Center at Parnassus Heights. The patient was then discharged and three months later, the patient successfully underwent heart transplantation. The announcement stated that the patient continues to recover well and looks forward to returning home to care for his young daughter with renewed strength and health. The procedures were performed by cardiac surgeon Amy Fiedler, M.D., Surgical Director of the Heart Transplant and Mechanical Circulatory Support Program, and Jason W. Smith, M.D., Chief of Cardiac Surgery and Lung Transplantation. UCSF has one of the largest heart transplant programs in the country and, in Northern CA, has the only active program that fully implants the mechanical heart. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical Inc., commented, “This fifth case at UCSF highlights the continued clinical adoption of the SynCardia Total Artificial Heart at leading transplant centers and now has a corresponding successful heart transplantation. For patients in advanced biventricular failure, time is critical. The ability to stabilize and sustain these patients, so that they are also healthy enough for surgery until a suitable donor heart becomes available is central to our mission.” Picard Medical Inc is also advancing development of the Emperor TAH, a fully implantable next generation device designed to expand access to long-term mechanical circulatory support without the need for external pneumatic drivers. About UCSF Health UCSF Health is recognized worldwide for its innovative patient care, reflecting the latest medical knowledge, advanced technologies and pioneering research. It includes the flagship UCSF Medical Center, which is among the nation’s top specialty hospitals, as well as UCSF Benioff Children Hospitals with campuses in San Francisco and Oakland; two community hospitals, UCSF Health Stanyan Hospital and UCSF Health Hyde Hospital; Langley Porter Psychiatric Hospital; UCSF Benioff Children Physicians; and the UCSF Faculty Practice. UCSF Health UCSF Medical Center ranks among the country’s top specialty hospitals for adult care, according to U.S. News and World Report, and is best in the San Francisco Metro Area in Cardiology, Heart and Vascular Surgery. UCSF Health excels in numerous complex cardiology procedures and conditions and received the highest rating, High Performing, for aortic valve surgery, as well as specialty care for heart arrhythmias, heart attacks, heart failure, and pacemaker implantation. These hospitals serve as the academic medical center of the University of California, San Francisco, which is world renowned for its graduate level health sciences education and biomedical research. UCSF Health maintains affiliations with hospitals and health organizations throughout the Bay Area. For more information, visit https://ucsfhealth.org. About Picard Medical and SynCardia Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. Contact: InvestorsEric RibnerManaging DirectorLifeSci Advisors LLCeric@lifesciadvisors.com Picard Medical, Inc./SynCardia Systems, LLCIR@picardmedical.com General/MediaBrittany Lanzablanza@syncardia.com

-Picard Medical / SynCardia Systems LLC mark historic milestone as a patient reaches 2,900 days of continuous support with the SynCardia Total Artificial Heart — the longest timeframe in the world ever recorded- TUCSON, Ariz., Dec. 09, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, proudly marks a new milestone in the field of mechanical circulatory support with a patient living over eight years or 2,900 days with a SynCardia™ Total Artificial Heart (STAH), the longest timeframe that a patient has ever lived on an artificial heart. “This achievement shows the life-changing impact of the SynCardia Total Artificial Heart, offering not only a bridge to transplant but also durable long-term support, to support life far beyond the typical time span for patients waiting for a donor heart,” said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical. “In this case, the STAH demonstrates long-term durability and reliability as well as fills a life-saving gap for patients who would otherwise have no viable options. Building on this foundation of long-term success, Picard Medical is now developing the Emperor, its next generation of fully implantable, artificial heart systems to broaden access and provide greater flexibility for long-term support worldwide.” About the Patient A 46-year-old patient, facing end-stage heart failure, received the SynCardia Total Artificial Heart on December 9, 2017 at the Institute for Cardiovascular Diseases, Dedinje hospital (also known as “IVDK Dedinje Hospital”) in Belgrade, Serbia. Today, eight years later, this patient continues to live supported by the SynCardia Total Artificial Heart, reaching more than 2,900 days of extended life, with most of those days spent at home with family and loved ones. The dedication of the medical team at IVDK Dedinje Hospital, combined with SynCardia’s technology, continues to make a profound difference in this patient’s journey. Long-term Success Concentrated in Serbia Serbia continues to lead the world in long-duration support with the SynCardia Total Artificial Heart. The five longest supported patients globally are all from IVDK Dedinje Hospital in Belgrade, with one patient supported for about eight years, another for more than four years, a third for more than three years, and two additional patients each supported for just under three years. These extraordinary cases reflect the strength of the clinical program in the region and the dedication of Serbian cardiac surgeons and transplant teams at IVDK Dedinje Hospital, who have advanced the SynCardia Total Artificial Heart at an exceptional level. About Picard Medical and SynCardia Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov. Contact: InvestorsEric RibnerManaging DirectorLifeSci Advisors LLCeric@lifesciadvisors.com Picard Medical, Inc./SynCardia Systems, LLCIR@picardmedical.com General/MediaBrittany Lanzablanza@syncardia.com

TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5th through 6th, 2025 in Frankfurt, Germany.